New dual-target drug may help overcome immunotherapy resistance in pancreatic cancer

The drug, SH-273, led to long-term tumor reduction in mouse models

5:00 AM

Author | Ananya Sen

big microscope two scientist holding with green background
Justine Ross, Michigan Medicine

Pancreatic ductal adenocarcinoma is one of the deadliest cancer types, with a five-year survival rate of 13%.

There are only two treatment regimens available with limited efficacy.

Pancreatic cancers do not respond to immunotherapy where the body’s immune system attacks tumor cells.

The effectiveness of these treatments is limited due to immunotherapy resistance.

During this process, myeloid and regulatory B cells of the immune system suppress other immune mechanisms from attacking pancreatic tumors.

A team of researchers from the College of Pharmacy and Rogel Cancer Center at the University of Michigan has developed a new strategy to improve immunotherapy treatments.

Immune resistance in pancreatic cancer is complicated because there are multiple resistance pathways. We wanted to develop a drug molecule that could adaptively stimulate the helpful pathways while inhibiting the harmful ones.”  

-Duxin Sun, Professor of Pharmaceutical Sciences

“Immune resistance in pancreatic cancer is complicated because there are multiple resistance pathways,” said Duxin Sun, U-M Professor of Pharmaceutical Sciences.

“We wanted to develop a drug molecule that could adaptively stimulate the helpful pathways while inhibiting the harmful ones.” 

Previously, researchers had identified compounds that boost the effectiveness of immunotherapy agents called STING agonists.

STING, or STimulator of Interferon Genes, activates specific parts of the immune system, helping the body fight tumors.

Although STING agonists were able to overcome immunotherapy resistance driven by myeloid cells, they also induced resistance by increasing the number of regulatory B cells.

In the new study, the team found that STING agonists activate myeloid cells independent of the enzyme PI3Kγ but increase the number of regulatory B cells through PI3Kγ.

The researchers showed that in mouse models and human cells derived from patients with pancreatic cancer, using STING agonists and inhibiting PI3Kγ can improve immunotherapy pathways.

Based on this discovery, they developed a dual-targeting compound, SH-273, to simultaneously activate STING and inhibit PI3Kγ.

The drug increased the survival of pancreatic cancer mouse models to 201 days, while most therapeutics do not show any efficacy in these mice that bear the same mutations as human pancreatic cancers.

It also decreased tumor metastasis and invasion in the lungs and was not toxic to the animals.

“It is significant that a treatment has improved survival for such a long time in mice with pancreatic tumors,” Sun said.

“Our findings point to a new therapeutic concept for pancreatic cancer—keeping the immune system’s ‘go’ signals on, while shutting down the B cell brake that fuels resistance.”

The team hopes to advance SH-273 in phase 1 trials and will continue to investigate additional immune mechanisms that can be harnessed to overcome immunotherapy resistance.

Additional authors: Chengyi Li, Fang Ke, Hongyi Zhao, Shuai Mao, Mahamadou Djibo, Linqi Huang, Miao He, Meilin Wang, Hanning Wen, Zhongwei Liu, Zhixin Yu, Zhihong Qi, Ana R. Xavier, Minal Nenwani, Bo Wen, Nicole Peterson, Vaibhav Sahai, Deepak Nagrath, Carrie L. Lucas, Matthias P. Wymann, Wei Gao and Lawrence Fong.

Funding/disclosures: This study is partially supported by the Michigan Translational Research and Commercialization grant and internal funding from University of Michigan.

Tech transfer(s)/Conflict(s) of interest: The University of Michigan has submitted a patent application, in which Duxin Sun, Chengyi Li, Wei Gao, Bo Wen, Meilin Wang, Miao He, Hongyi Zhao, Shuai Mao, Mahamadou Djibo, Zhongwei Liu, Hanning Wen and Fang Ke are listed as inventors.

Michigan Research Core(s): Pharmacokinetics and Mass Spectrometry Core, Flow Cytometry Core, Microscopy Core and Advanced Genomics Core.

Paper cited: “Dual Targeting of PI3Kγ and STING Overcomes Regulatory B Cell- and Myeloid Cell-Driven Immune Suppression in Pancreatic Cancer,” Nature Cancer. DOI: 10.1038/s43018-026-01158-7

Sign up for Health Lab newsletters today. Get medical tips from top experts and learn about new scientific discoveries every week

Sign up for the Health Lab Podcast. Add us wherever you listen to your favorite shows


More Articles About:

Pancreatic cancer Rogel Cancer Center Cancer (Oncology) All Research Topics
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Related

blue body with red organ lit up
Health Lab

Drug targets identified for pancreatic cancer

U-M researchers have discovered that simultaneously targeting PIKfyve and KRAS-MAPK can eliminate tumors in preclinical human and mouse models.
microscopic image close up colorful blue red yellow
Health Lab

Study finds cancer cells use a new fuel in absence of sugar

Sugar free: investigator finds cancer cells use a new fuel in absence of sugar

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

normal pancreas drawing and one labeled PDAC
Health Lab

Gut microbiome may influence how patients with pancreatic cancer respond to treatment

Microbes create unique communities called microbiomes in the gut, oral cavity, skin and urogenital regions. Donnele Daley discusses common misconceptions about “healthy” microbes, the role of microbiomes in pancreatic cancer and future research directions.
Alarm clock sitting on a white dinner plate with blue and yellow flowers on the rim and a fork and knife positioned on either side of the plate.
Health Lab

Intermittent fasting can reverse diabetes in mice, study finds

Study shows intermittent fasting and meal timing can help reverse type 2 diabetes by resting pancreatic beta cells
Man sits in a medical exam room looking at caregiver whose back is to camera and looks toward a computer screen.
Health Lab

Updated prostate cancer screening guidelines emphasize benefits of early detection

New guidelines for prostate cancer screening focus on early detection and individual risk.
Mother sits on a couch with a laptop on her lap while an elementary school age boy sits next to her playing on a tablet device.
Health Lab

New questionnaire aims to improve understanding of demand avoidance in children, teens

Pathological demand avoidance is a pattern of intense distress and avoidance of demands in children. A new questionnaire from University of Michigan researchers creates a structured way to assess these behaviors.
Blue round cells in three pictures showing how they change under stress.
Health Lab

Timing is of the essence for RNA during stress

Key determiners of which RNA can be read to make proteins is time. Previous thinking was that a cell under threat would quickly make these RNAs in the nucleus and immediately push them into the cytoplasm.
Blue and yellow illustration of DNA helix
Health Lab

New anti-cancer strategy shows promise in preclinical studies

New cancer therapeutic strategy rewires protein interactions to improve efficacy and reduce potential side effects.